Arvinas Shares Soar on Surprise Profit and VEPPANU Approval Milestone

Shares of Arvinas (ARVN) surged over 13% in morning trading after the biotechnology company reported a significant second-quarter earnings beat, fueled by a milestone payment related to the recent FDA approval of its drug, VEPPANU.

Financials Exceed Expectations

Arvinas announced second-quarter earnings per share of $2.58, starkly contrasting with the analyst consensus forecast for a loss of $0.38. Revenue for the quarter came in at $249.7 million, vastly outperforming the expected $58.61 million.

The substantial revenue was primarily driven by several one-time events rather than commercial sales. According to the company's release, these included:

• A $50.0 million development milestone payment for the FDA's approval of VEPPANU.
• $62.5 million from a licensing agreement with Rigel Pharmaceuticals.
• $126.4 million recognized from its original Pfizer collaboration, as deferred revenue was released upon entering the Rigel deal.

Strategic Drug Approval and Pipeline

Ad

The FDA's approval of VEPPANU marks a major achievement for Arvinas. CEO Randy Teel stated that the subsequent licensing of the drug to Rigel Pharmaceuticals is intended to "unlock its commercial potential and provide patient access as efficiently as possible."

Looking ahead, the company highlighted upcoming clinical data readouts from three Phase 1 programs—ARV-393, ARV-102, and ARV-027—which are anticipated over the next 12 months. Arvinas also presented promising preclinical data for its HPK1 degrader program, ARV-6723, which showed potential in overcoming resistance to immune checkpoint inhibitors in solid tumors.

Investor Outlook

While the revenue outperformance was largely attributable to non-recurring items, investors responded positively to the company's strengthened financial position. The transactions have extended Arvinas's cash runway into the second half of 2028, providing significant operational stability.

The stock's rally occurred amid a constructive market backdrop, with the S&P 500 and Nasdaq Composite both trading higher. According to data cited by Investing.com, analysts covering Arvinas hold an average "Buy" rating with a 12-month price target of $14.80.